Cat. No.: HY-106950

Fosfructose

(Synonyms: Diphosphofructose; Esafosfan; FDP)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Fosfructose is an orally active cyclooxygenase-2 inhibitor and Toll-like receptor 4 modulator. Fosfructose reduces the expression of cyclooxygenase-2, thereby decreasing prostaglandin production. By inhibiting the Toll-like receptor 4 signaling pathway, Fosfructose downregulates LPS-induced adhesion molecule expression. Fosfructose is applicable to research related to ischemic stroke, epilepsy, sepsis, myocardial injury, osteoporosis, and ultraviolet B-induced skin damage.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 488-69-7
Formula: C₆H₁₄O₁₂P₂
Molecular Weight:340.12

Storage:

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Fosfructose Chemical Structure

CAS No.: 488-69-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Human Endogenous Metabolite

All Toll-like Receptor (TLR) Isoforms :

All COX Isoforms :

In Vitro

Fosfructose (0.5-2%) concentration-dependently inhibits protein oxidation in cell-free human serum albumin assays^[1].
Fosfructose (5-10 mM) concentration-dependently increases metabolism in hypoxic rat cardiomyocytes and increases membrane fluidity in lipid vesicles^[1].
Fosfructose (3.5 mM) inhibits cyanide- and iodoacetate-induced intracellular calcium increases in cultured astrocytes and adult rat brain slices^[1].
Fosfructose (1-20 mM; 24 h post-irradiation for 10 mM) dose-dependently reduces UVB-induced intracellular oxidation in HaCaT cells, and 10 mM (24 h post-irradiation) inhibits COX-2 expression, prostaglandin production, and increases GSH levels^[1].
Fosfructose (10-20 mM; 24 h post-treatment) concentration-dependently protects mouse cortical neurons from NMDA-induced excitotoxicity by reducing ROS production and neuronal death^[1].
Fosfructose (10 mM; 20 min reperfusion) improves ATP + ADP preservation and ATP recovery in isolated rat liver mitochondria following ischemia-reperfusion injury^[1].
Fosfructose (5 mM) reduces K⁺ permeability, preserves Na⁺/K⁺ ATPase activity, and inhibits TNF-α-induced apoptosis in GalN-treated isolated rat hepatocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fosfructose (2 g/kg; i.p.; single post-insult dose) reverses galactosamine-induced hepatitis in Wistar rats by improving hepatic carbohydrate metabolism and reducing apoptotic and necrotic liver damage^[1].
Fosfructose (0.5 g/kg; i.p.; single dose) reduces sepsis-induced inflammatory markers and achieves 50% 7-day survival in Wistar rats^[1].
Fosfructose (2 g/kg; i.p.; single dose; at sepsis induction) inhibits sepsis-induced platelet aggregation and coagulation abnormalities in Wistar rats^[1].
Fosfructose (500 mg/kg; i.p.; single pre-insult dose) drastically improves long-term survival in mice with Candida albicans-induced candidemia^[1].
Fosfructose (i.p.) reverses cisplatin-induced acute renal failure in Wistar rats^[1].
Fosfructose (i.p.) reduces doxorubicin-induced cardiac histological damage in Wistar rats^[1].
Fosfructose (2 g/kg; i.p.; single dose) reverses hypothermia-induced oxidative stress and metabolic acidosis in Wistar rats^[1].
Fosfructose (1.0 g/kg; i.p.; single pre-kindling dose) delays seizure acquisition in a rat rapid hippocampal kindling model by modulating BDNF/TrkB signaling and cation-chloride cotransporter expression^[1].
Fosfructose (0.5-1 g/kg; i.p.; single pre-insult dose) exerts a dose-dependent anticonvulsant effect in rats with chemically induced acute seizures, increasing seizure latency and reducing seizure duration and severity^[1].
Fosfructose (0.5-1 g/kg; i.p.; single pre-convulsion dose) protects hippocampal mitochondrial function and synaptic structure in immature rats with repeated febrile convulsions^[1].
Fosfructose (350 mg/kg; i.v.; twice daily; 7 days), combined with an immunosuppressant, quadruples heterotropic heart transplant survival in Mus musculus (mice) by inhibiting T-lymphocyte proliferation and IL-2 production^[1].
Fosfructose (9 mM; topical; once daily for 3 days pre-irradiation; immediately post-irradiation) preserves skin antioxidant capacity and reduces UVB-induced oxidative stress in hairless mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar (galactosamine-induced hepatitis)^[1]
Dosage:

2 g/kg
Administration:

i.p.; single post-insult dose
Result:

Reversed galactosamine-induced liver damage.
Improved hepatic carbohydrate metabolism.
Reduced indexes of apoptosis and necrosis in liver tissue.

Animal Model:

Wistar (intraperitoneal LPS-containing capsule-induced sepsis)^[1]
Dosage:

0.5 g/kg
Administration:

i.p.; single dose
Result:

Reduced leukocytosis and tissue edema at 6 hours post-sepsis induction.
Achieved 50% survival of treated animals beyond 7 days of sepsis.

Animal Model:

Wistar (direct cecal puncture-induced sepsis)^[1]
Dosage:

2 g/kg
Administration:

i.p.; single dose; at sepsis induction
Result:

Inhibited platelet aggregation and other coagulation abnormalities at 12 hours post-sepsis induction.

Animal Model:

Mice (intratracheal instillation of Candida albicans-induced candidemia)^[1]
Dosage:

500 mg/kg
Administration:

i.p.; single pre-insult dose
Result:

Drastically improved survival beyond 15 days post-candidemia induction.

Animal Model:

Wistar (hypothermia-induced oxidative stress)^[1]
Dosage:

2 g/kg
Administration:

i.p.; single dose
Result:

Reversed hypothermia-induced increases in ROS production.
Reversed hypothermia-induced reduction in antioxidant enzyme activities.
Reversed hypothermia-induced blood metabolic acidosis.

Animal Model:

Wistar (rapid hippocampal kindling-induced seizure susceptibility)^[1]
Dosage:

1.0 g/kg
Administration:

i.p.; single pre-kindling dose
Result:

Significantly delayed kindling acquisition.
Delayed the upregulation of BDNF and TrkB mRNAs in the hippocampus.
Prevented kindling-induced KCC2 downregulation.
Decreased NKCC1 expression to reduce intracellular chloride accumulation.

Animal Model:

Wistar (kainic acid, pilocarpine, or pentylenetetrazol injection-induced acute seizures)^[1]
Dosage:

0.5 g/kg, 1 g/kg
Administration:

i.p.; single pre-insult dose
Result:

Produced a dose-dependent anticonvulsant effect.
Reduced seizure duration and severity.
Significantly increased seizure latency.

Animal Model:

immature rats (hot water immersion-induced repeated febrile convulsions)^[1]
Dosage:

0.5 g/kg, 1 g/kg
Administration:

i.p.; single pre-convulsion dose
Result:

Protected hippocampal mitochondrial structure and function.
Protected against synaptic damage.
Did not prevent neuronal degeneration.

Animal Model:

Mice (heterotropic heart transplant rejection)^[1]
Dosage:

350 mg/kg
Administration:

i.v.; twice daily; 7 days
Result:

Improved heart transplant survival four-fold compared to non-treated animals, with a greater effect than the immunosuppressant alone.
Reduced induced T-lymphocyte proliferation.
Prevented increases in IL-2 production.

Animal Model:

Hairless mice (4 days of 100 mJ/cm² UVB irradiation-induced skin damage)^[1]
Dosage:

9 mM
Administration:

topical; once daily for 3 days pre-irradiation; immediately post-irradiation
Result:

Penetrated the skin.
Preserved cellular antioxidant capacity (GSH content and catalase activity).
Reduced oxidative stress markers (protein carbonyls) in both dermis and epidermis.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 488-69-7
Appearance Oil
Molecular Weight 340.12
Formula C₆H₁₄O₁₂P₂
Color White to off-white
SMILES

O=P(O)(O)OCC([C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)=O
Synonyms

Diphosphofructose; Esafosfan; FDP
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Metabolic Imbalance Triggers Adaptive Remodeling to Accelerate Diploidization in Murine Haploid Embryonic Stem Cells. [Abstract]

2026 Apr 22:e22570. PMID: 42018132

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (73.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9401 mL

14.7007 mL

29.4014 mL

5 mM

0.5880 mL

2.9401 mL

5.8803 mL

10 mM

0.2940 mL

1.4701 mL

2.9401 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Alva N, et al. Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism. Curr Med Chem. 2016;23(39):4396-4417. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9401 mL	14.7007 mL	29.4014 mL	73.5035 mL
	5 mM	0.5880 mL	2.9401 mL	5.8803 mL	14.7007 mL
	10 mM	0.2940 mL	1.4701 mL	2.9401 mL	7.3503 mL
	15 mM	0.1960 mL	0.9800 mL	1.9601 mL	4.9002 mL
	20 mM	0.1470 mL	0.7350 mL	1.4701 mL	3.6752 mL
	25 mM	0.1176 mL	0.5880 mL	1.1761 mL	2.9401 mL
	30 mM	0.0980 mL	0.4900 mL	0.9800 mL	2.4501 mL
	40 mM	0.0735 mL	0.3675 mL	0.7350 mL	1.8376 mL
	50 mM	0.0588 mL	0.2940 mL	0.5880 mL	1.4701 mL
	60 mM	0.0490 mL	0.2450 mL	0.4900 mL	1.2251 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Fosfructose

Immunology/Inflammation Compound Library

Natural Product Library

Clinical Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Pyroptosis Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Food-Sourced Compound Library

Human Metabolite Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Animal-Sourced Natural Product Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Amino Acid Metabolite Compound Library

Pattern Recognition Receptors Library

Lactic Acid Metabolite Compound Library

Carbohydrate Metabolite Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Fosfructose

All Toll-like Receptor (TLR) Isoforms

All COX Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Fosfructose Related Classifications

HY-106950 Related Classifications